Latest Research, Industry, Medical and Scientific News
LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Cogentix Medical Inc., (NASDAQ: CGNT) for $3.85 per Cogentix share in cash, and an enterprise value of $214 million. Cogentix is a global medical company that provides proprietary, innovative technologies to a number of specialty markets including urology. “The acquisition of Cogentix advances our strategy to invest in leading technologies that provide product and channel scale to LABORIE’S existing Urology Strategic Business Unit (SBU) diagnostic and therapeutic portfolio, particularly in the areas of OAB (overactive bladder) and SUI (stress urinary incontinence),” commented Michael Frazzette, President & CEO of LABORIE Medical Technologies. “The addition of Cogentix’s suite of technology will significantly expand LABORIE’S therapeutic offering, thereby providing customers and their patients with comprehensive, clinically-relevant solutions along the disease treatment continuum.” Read more.
Source: Market Insider, March 12, 2018
Tokyo-based Astellas Pharma (TYO: 4503) has been awarded EU approval for its neurogenic detrusor overactivity (NDO) therapy solifenacin succinate in oral suspension form. The drug is indicated for children aged 2 to 18 years. NDO is a bladder dysfunction in which increased storage pressure can put the upper urinary tract at risk of deterioration. Commonly observed in patients with conditions such as multiple sclerosis and spinal cord injury, it causes urinary incontinence in approximately 50% of MS patients. Read more.
Source: The Pharma Letter, March 9, 2018
Patients with cardiovascular risk factors are more likely to also experience urgency urinary incontinence (UUI), according to UK researchers. They also said their study findings indicated that severe urgency UUI was a “distinct disease” from milder forms of the condition.The researchers, from University College London and King’s College London, looked at data on 1,762 participants in a Medical Research Council survey who reported having incontinence at the age of 68. The prevalence of urinary incontinence was 15% in men and 54% in women. UUI was the most common subtype in men, while there were similar proportions of UUI and stress urinary incontinence in women, with it being reported by 12% of men and 19% of women. Read more.
Source: Nursing Times online, March 9, 2018
Triple W, a startup company that develops the first connected wearable device that can track the progression of bladder movements using non-invasive ultrasonic sensors, announced today that their product will be released in the US later this year. The device will help elderly and disabled people who suffer from incontinence by notifying when they will need to go to the bathroom. As a result, users no longer have to worry about accidents and can often forgo the embarrassment of wearing diapers. According to a report released by CDC, more than 50 percent of older Americans struggle with incontinence. Incontinence occurs when muscles are too weak or too active. There are other causes of incontinence, such as prostate problems and nerve damage. Read more.
Source: PRNewswire, March 5, 2018
GTx, Inc. (Nasdaq:GTXI) today announced additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence (SUI), including magnetic resonance imaging (MRI) results from patients’ pelvic floor muscle. New data in a subset of women also suggests a positive treatment effect of enobosarm for urge incontinence (UI) suggesting a possible treatment effect for women with mixed incontinence. Results from a pre-specified analysis of MRI data demonstrate a statistically significant increase in pelvic floor muscle thickness and urethral muscle diameter after enobosarm treatment. Treatment with enobosarm also reduced mean UI episodes by approximately 68 percent in patients who experienced UI as well as SUI, based on a post hoc analysis of a subset of women with both UI and SUI. These results were outlined during a podium presentation which took place at the Society of Urodynamics, Female Pelvic Medicine, & Urogenital Reconstruction (SUFU) 2018 Meeting on Saturday, March 3, 2018. The presentation included clinical data from all 18 patients completing 12 weeks of enobosarm treatment, which, as previously reported, demonstrated an 81 percent reduction in the number of mean stress leaks per day (the primary endpoint of the clinical trial), as well as additional data demonstrating duration of response following completion of treatment, including nine patients who have now reached seven months post-treatment. Read more.
Source: Business Wire, March 5, 2018
StimGuard yesterday announced plans for a clinical trial comparing its nerve stimulator with the InterStim sacral nerve stimulator made by Medtronic (NYSE:MDT). Pompano Beach, Fla.-based StimGuard is already running a pivotal study of its technology, a miniature implantable device designed to treat urinary incontinence resulting from refractory overactive bladder syndrome. The device is implanted at the tibial nerve through a needle-sized introducer and uses wireless technology to stimulate the nerve. Read more.
Source: Massdevice, March 1, 2018